{
    "organizations": [],
    "uuid": "1a2ee79303bd94626b222c755899901aae0c4d02",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-genentech-says-in-phase-3-impower1/brief-genentech-says-in-phase-3-impower150-study-survival-advantage-for-tecentriq-avastin-combo-was-seen-in-all-exploratory-patient-subgroups-analyzed-idUSFWN1SN0YY",
    "ord_in_thread": 0,
    "title": "BRIEF-Genentech Says In Phase 3 Impower150 Study, Survival Advantage For Tecentriq-Avastin Combo Was Seen In All Exploratory Patient Subgroups Analyzed",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 16 (Reuters) - GENENTECH:\n* PHASE III IMPOWER150 STUDY SHOWED GENENTECHâ€™S TECENTRIQ AND AVASTIN PLUS CARBOPLATIN AND PACLITAXEL HELPED PEOPLE WITH A SPECIFIC TYPE OF METASTATIC LUNG CANCER LIVE SIGNIFICANTLY LONGER COMPARED TO AVASTIN PLUS CARBOPLATIN AND PACLITAXEL\n* GENENTECH - IN PHASE III IMPOWER150 STUDY, SURVIVAL ADVANTAGE FOR TECENTRIQ-AVASTIN COMBO REGIMEN WAS SEEN IN ALL EXPLORATORY PATIENT SUBGROUPS ANALYZED Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-17T05:16:00.000+03:00",
    "crawled": "2018-05-17T01:45:50.011+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "genentech",
        "phase",
        "iii",
        "impower150",
        "study",
        "showed",
        "genentech",
        "tecentriq",
        "avastin",
        "plus",
        "carboplatin",
        "paclitaxel",
        "helped",
        "people",
        "specific",
        "type",
        "metastatic",
        "lung",
        "cancer",
        "live",
        "significantly",
        "longer",
        "compared",
        "avastin",
        "plus",
        "carboplatin",
        "paclitaxel",
        "genentech",
        "phase",
        "iii",
        "impower150",
        "study",
        "survival",
        "advantage",
        "combo",
        "regimen",
        "seen",
        "exploratory",
        "patient",
        "subgroup",
        "analyzed",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}